Thermo Fisher Scientific Inc. $TMO Shares Sold by Aviva PLC

Key Points

• Aviva PLC reduced its Thermo Fisher Scientific stake by 3.6% in the fourth quarter, selling 15,042 shares and leaving it with 406,165 shares valued at about $235.4 million.
• Thermo Fisher reported solid quarterly results, with EPS of $5.44 topping expectations and revenue of $11.01 billion also beating forecasts; revenue rose 6.2% year over year.
• Insider and analyst activity remains active: COO Gianluca Pettiti sold 400 shares under a pre-arranged trading plan, while analysts currently rate the stock a “Moderate Buy” with an average target price of $608.95.

Aviva PLC lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 406,165 shares of the medical research company's stock after selling 15,042 shares during the period. Aviva PLC owned 0.11% of Thermo Fisher Scientific worth $235,352,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of TMO. Vanguard Group Inc. lifted its stake in shares of Thermo Fisher Scientific by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company's stock worth $19,778,774,000 after acquiring an additional 288,296 shares during the period. Capital World Investors lifted its stake in shares of Thermo Fisher Scientific by 7.0% in the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company's stock worth $6,376,229,000 after acquiring an additional 718,669 shares during the period. Geode Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company's stock worth $4,728,129,000 after acquiring an additional 26,425 shares during the period. Franklin Resources Inc. lifted its stake in shares of Thermo Fisher Scientific by 7.1% in the 4th quarter. Franklin Resources Inc. now owns 6,346,512 shares of the medical research company's stock worth $3,677,486,000 after acquiring an additional 420,841 shares during the period. Finally, Norges Bank acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $3,072,744,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares of the company's stock, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $475.12 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99. The firm has a 50 day moving average price of $479.68 and a 200 day moving average price of $528.09. The company has a market cap of $176.56 billion, a price-to-earnings ratio of 26.12, a PEG ratio of 2.13 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. Thermo Fisher Scientific's revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific's payout ratio is 10.34%.

Analyst Upgrades and Downgrades

TMO has been the subject of several recent analyst reports. Stifel Nicolaus reduced their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating for the company in a research note on Friday, April 24th. Piper Sandler initiated coverage on shares of Thermo Fisher Scientific in a research note on Thursday. They issued a "neutral" rating and a $510.00 target price for the company. KeyCorp restated an "overweight" rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a research note on Friday, May 8th. Finally, Robert W. Baird reduced their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a research note on Friday, April 24th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $608.95.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.